(Q24245431)

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immuno

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

Oral Fabrol (oral N-acetyl-cysteine) in chronic bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

N‐isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. British Thoracic Society Research Committee

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

Effect of long-term treatment with sobrerol on the exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: a double-blind placebo controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

S-carboxymethylcysteine in the fluidification of sputum and treatment of chronic airway obstruction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021

Summary of the National Mucolytic Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB2

7 January 2021